Therapy News and Research

RSS

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

AFREZZA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented today at the American Diabetes Association's 70th Scientific Sessions.

29 Jun 2010

Young breast cancer patients more likely to discontinue hormone therapy

A new study of nearly 8,800 women with early-stage breast cancer found that fewer than half - approximately 49 percent - completed their full regimen of hormone therapy according to the prescribed schedule.

29 Jun 2010

Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act signed into law

The President signed into law on Friday, June 25, 2010, The Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act. The bill was approved by the U.S. House of Representatives by a vote of 417 to 1. The Senate had earlier approved the measure.

29 Jun 2010

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Marcadia Biotech, Inc. and Eli Lilly and Company today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a glucagon analog that is in preclinical development at Marcadia, as well as related backup compounds.

29 Jun 2010

Literature review discusses herniated disks and treatment options for low back pain

A literature review, led by Dr. Joseph Lee, published in the June 2010 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) suggests that a herniated disk is one of the most frequent causes of low back and leg pain in adults, but surgery is not for everyone. Between 60 and 80 percent of people will experience low back pain at some point in their lives

29 Jun 2010

Failed ACL surgeries are more common than previously thought

Nick Van Erp, active in soccer since elementary school and lacrosse since junior high, tore the anterior cruciate ligament in his knee during a spring lacrosse game his freshman year of high school. His injury, caused by stepping into a pothole and hyper-extending his knee, required surgical repair, ending his season prematurely and the remainder of his high school sports career.

29 Jun 2010

EpiCept requests FDA priority review of Ceplene NDA for AML

EpiCept Corporation announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene® (histamine dihydrochloride). EpiCept is seeking approval for Ceplene, administered concomitantly with low-dose interleukin-2 (IL-2), for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first complete remission.

29 Jun 2010

New brain-to-computer chip technology revolutionizes neurological therapy

By stimulating certain areas of the brain, scientists can alleviate the effects of disorders such as depression or Parkinson's disease. That's the good news. But because controlling that stimulation currently lacks precision, over-stimulation is a serious concern - losing some of its therapeutic benefits for the patient over time.

29 Jun 2010

Efforts to contain drug-resistant malaria near Thai-Cambodian border appear to be working, officials say

A two-year effort aimed at preventing the emergence of drug-resistant malaria near the border between Cambodia and Thailand is showing signs of success, Duong Socheat, head of Cambodia's National Center for Malaria Control, said on Friday, DPA/Earth Times reports.

29 Jun 2010

A neuro-optometric rehabilitation case report

The College of Optometrists in Vision Development (COVD) has posted its current issue of Optometry & Vision Development online and invites all to read the full-text articles free of charge.

29 Jun 2010

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.

28 Jun 2010

MagForce's Nano-Cancer therapy receives European regulatory approval

Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.

28 Jun 2010

Aestus Therapeutics announces license agreement with Astellas Pharma

Aestus Therapeutics, Inc. announced today a license agreement with Astellas Pharma Inc. (Astellas; Tokyo, Japan) to provide Aestus with exclusive, world-wide rights to the Astellas product FK614. Aestus will develop the product as ATx08-001, a novel, first-in-class therapeutic for the treatment of neuropathic pain. The first clinical trial will start later this year.

28 Jun 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool.

28 Jun 2010

12 new gene variants that impact individual's risk of developing type 2 diabetes identified

An international consortium including Helmholtz Zentrum München and the German Diabetes Center, Düsseldorf has identified 12 new gene variants which impact the individual's risk of developing type 2 diabetes. The study represents a major contribution towards elucidating the complex pathogenesis of this important widespread disease. Nature Genetics has published the findings of this study in its current issue.

28 Jun 2010

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Cancer Research UK scientists have discovered certain ovarian tumour cells that are resistant to chemotherapy can survive a first round of treatment and go on to "re-grow" the cancer. This could help explain why the disease can be difficult to treat, according to new research published in Oncogene today (Monday).

28 Jun 2010

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

28 Jun 2010

ADVANCE study provides new insights into the management of SHPT in CKD patients

Results from the ADVANCE study presented in a late breaking clinical trial session at the ERA-EDTA 2010 Congress provide new insights into the management of secondary hyperparathyroidism in chronic kidney disease patients. ADVANCE (A randomiseD VAscular calcificatioN study to evaluate the effects of CinacalcEt) is a randomised, controlled open label study to evaluate the effects of treatment with Mimpara (cinacalcet) plus low-dose vitamin D, compared to flexible doses of vitamin D alone, on the progression of vascular and valvular calcification in dialysis patients with SHPT.

28 Jun 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Therapy News and Research

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

Young breast cancer patients more likely to discontinue hormone therapy

Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act signed into law

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Literature review discusses herniated disks and treatment options for low back pain

Failed ACL surgeries are more common than previously thought

EpiCept requests FDA priority review of Ceplene NDA for AML

New brain-to-computer chip technology revolutionizes neurological therapy

Efforts to contain drug-resistant malaria near Thai-Cambodian border appear to be working, officials say

A neuro-optometric rehabilitation case report

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

MagForce's Nano-Cancer therapy receives European regulatory approval

Aestus Therapeutics announces license agreement with Astellas Pharma

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

12 new gene variants that impact individual's risk of developing type 2 diabetes identified

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

ADVANCE study provides new insights into the management of SHPT in CKD patients

Linagliptin mono- and combination therapy improves blood glucose control

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News